Lefèvre G, Gauron S
Novartis Pharma AG, Basle, Switzerland.
J Chromatogr B Biomed Sci Appl. 2000 Jan 28;738(1):129-36. doi: 10.1016/s0378-4347(99)00509-5.
A fully automated high-performance liquid chromatography method with fluorescence detection for the determination of the renin inhibitor CGP 60536 in animal and human plasma and urine has been developed and validated. After addition of an internal standard, the compounds were automatically extracted from 400 microl of plasma or urine with methyl alcohol-acetic acid (99:1, v/v) on 100-mg Bond-Elut CN cartridges using the Gilson ASPEC system. The on-line chromatographic separation was performed on a LiChrospher 100 RP8 5-microm particle size packed analytical column (25x0.4 cm I.D.). The mobile phase consisted of acetonitrile-0.01 M potassium dihydrogenphosphate (65:35, v/v) at a flow-rate of 0.8 ml/min. The analytes were detected using a fluorescence detector at excitation and emission wavelengths of 280 and 330 nm, respectively. The limit of quantitation was established at 4.5 ng/ml in plasma (accuracy 106% and precision 1%), and 9.0 ng/ml in urine (accuracy 101% and precision 13%). The method was applied to the investigation of the pharmacokinetics of CGP 60536.
已开发并验证了一种用于测定动物和人血浆及尿液中肾素抑制剂CGP 60536的全自动高效液相色谱荧光检测法。加入内标后,使用吉尔森ASPEC系统,在100毫克Bond-Elut CN柱上,用甲醇 - 乙酸(99:1,v/v)从400微升血浆或尿液中自动萃取化合物。在线色谱分离在LiChrospher 100 RP8 5微米粒径填充分析柱(25x0.4厘米内径)上进行。流动相由乙腈 - 0.01M磷酸二氢钾(65:35,v/v)组成,流速为0.8毫升/分钟。使用荧光检测器分别在激发波长280纳米和发射波长330纳米处检测分析物。血浆中的定量限为4.5纳克/毫升(准确度106%,精密度1%),尿液中的定量限为9.0纳克/毫升(准确度101%,精密度13%)。该方法应用于CGP 60536的药代动力学研究。